A Phase 1/2 Study of Array 520 in Patients with Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1/2 Study of Array 520 in Patients with Relapsed or Refractory Multiple Myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Filanesib (Primary) ; Dexamethasone; Filgrastim
  • Indications Multiple myeloma; Plasma cell leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Array BioPharma
  • Most Recent Events

    • 17 Aug 2017 Results (Data cut off March 16, 2016) published in the Cancer
    • 10 Jun 2017 Biomarkers information updated
    • 21 Apr 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top